News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Winston Pharmaceuticals, Inc. (WPHM.OB) Receives SBIR Grant from the National Institutes of Health (NIH) to Investigate Treatment for Postherpetic Neuralgia of the Trigeminal Nerve


4/9/2012 9:50:52 AM

VERNON HILLS, Ill.--(BUSINESS WIRE)--Winston Pharmaceuticals, Inc. (“Winston”), a specialty pharmaceutical company focused on developing and commercializing novel pain management therapies, announced that the National Institutes of Health (NIH) has awarded Winston a grant under the Small Business Innovation Research (SBIR) program supporting the development of Civamide, a proprietary TRPV-1 receptor modulator, for the treatment of postherpetic neuralgia (PHN) of the trigeminal nerve (TN). The Phase I award in the amount of approximately $375,000 will be administered by the National Institute of Neurological Disorders and Stroke (NINDS).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES